Glaxis Capital Management LLC Makes New $1.17 Million Investment in Quest Diagnostics Incorporated $DGX

Glaxis Capital Management LLC purchased a new position in shares of Quest Diagnostics Incorporated (NYSE:DGX) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 5,500 shares of the medical research company’s stock, valued at approximately $1,166,000. Quest Diagnostics comprises 2.3% of Glaxis Capital Management LLC’s investment portfolio, making the stock its 13th biggest position.

Several other institutional investors and hedge funds have also modified their holdings of the business. Moneta Group Investment Advisors LLC boosted its holdings in Quest Diagnostics by 3.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 1,387 shares of the medical research company’s stock worth $241,000 after purchasing an additional 50 shares in the last quarter. HB Wealth Management LLC boosted its stake in shares of Quest Diagnostics by 0.5% during the 4th quarter. HB Wealth Management LLC now owns 11,292 shares of the medical research company’s stock worth $1,960,000 after acquiring an additional 58 shares in the last quarter. Ossiam increased its holdings in shares of Quest Diagnostics by 6.1% during the 3rd quarter. Ossiam now owns 1,059 shares of the medical research company’s stock valued at $202,000 after acquiring an additional 61 shares during the last quarter. Independent Advisor Alliance increased its holdings in shares of Quest Diagnostics by 1.6% during the 4th quarter. Independent Advisor Alliance now owns 4,298 shares of the medical research company’s stock valued at $746,000 after acquiring an additional 66 shares during the last quarter. Finally, Checchi Capital Advisers LLC raised its stake in shares of Quest Diagnostics by 5.6% in the 4th quarter. Checchi Capital Advisers LLC now owns 1,326 shares of the medical research company’s stock valued at $230,000 after acquiring an additional 70 shares in the last quarter. Institutional investors and hedge funds own 88.06% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on DGX. JPMorgan Chase & Co. boosted their target price on Quest Diagnostics from $220.00 to $250.00 and gave the stock a “neutral” rating in a report on Tuesday, July 28th. Mizuho lifted their price target on shares of Quest Diagnostics from $235.00 to $260.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Barclays boosted their price objective on shares of Quest Diagnostics from $230.00 to $250.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Jefferies Financial Group reaffirmed a “buy” rating and set a $245.00 price objective on shares of Quest Diagnostics in a report on Thursday, July 23rd. Finally, Wall Street Zen upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a report on Tuesday, July 28th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $235.31.

Insiders Place Their Bets

In other Quest Diagnostics news, CEO J. E. Davis sold 10,000 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $194.14, for a total value of $1,941,400.00. Following the sale, the chief executive officer directly owned 132,423 shares in the company, valued at approximately $25,708,601.22. This trade represents a 7.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Mark E. Delaney sold 1,600 shares of the business’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $235.18, for a total value of $376,288.00. Following the completion of the transaction, the senior vice president directly owned 10,335 shares of the company’s stock, valued at approximately $2,430,585.30. The trade was a 13.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 19,747 shares of company stock valued at $3,947,088. 0.88% of the stock is currently owned by corporate insiders.

Quest Diagnostics Trading Up 0.0%

Shares of Quest Diagnostics stock opened at $241.80 on Friday. Quest Diagnostics Incorporated has a 12-month low of $171.18 and a 12-month high of $245.68. The stock has a market capitalization of $26.69 billion, a P/E ratio of 25.67, a price-to-earnings-growth ratio of 2.23 and a beta of 0.56. The company has a 50-day simple moving average of $218.52 and a 200 day simple moving average of $204.87. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.72.

Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $3.12 EPS for the quarter, topping analysts’ consensus estimates of $2.82 by $0.30. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%.The company had revenue of $3.04 billion for the quarter, compared to analyst estimates of $2.97 billion. During the same quarter in the previous year, the firm earned $2.62 earnings per share. The business’s revenue was up 10.2% on a year-over-year basis. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. Research analysts expect that Quest Diagnostics Incorporated will post 11.15 earnings per share for the current fiscal year.

Quest Diagnostics Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 21st. Stockholders of record on Tuesday, October 6th will be paid a dividend of $0.86 per share. This represents a $3.44 annualized dividend and a dividend yield of 1.4%. The ex-dividend date of this dividend is Tuesday, October 6th. Quest Diagnostics’s dividend payout ratio is 36.52%.

Quest Diagnostics Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.